Industry Outlook
The pharmaceutical intermediates market is set to reach from US$ 25,965.0 Mn in 2018 to US$ 36,890.6 Mn by 2027 at a compound annual growth rate (CAGR) of 4.0% during the forecast period from 2019 to 2027. Significant rise in drug formulation and research activities and supportive regulatory environment provided by global healthcare agencies will consolidate the pharmaceutical intermediates market during the forecast period.
Market Synopsis
Get a sample copy for more information
"Significant rise in drug formulation research & development (FR&D) activities to boost the bulk intermediates market growth"
Bulk drug intermediates are reigning the product segment for pharmaceutical intermediates market. The key driver associated with its market growth is the significant rise in the drug formulation research & development (FR&D). They are used as raw material in manufacturing of bulk drugs or as a secondary product generated during the synthesis of active pharmaceutical ingredient (API) having potential to be used in various drug formulation. Custom intermediates are gaining huge traction on account of increased drug development and research activities and burgeoning requirement of novel medicines to treat orphan diseases.
Get a sample copy for more information
"Rising prevalence of life threatening diseases and stringent regulatory norms imposed by healthcare agencies worldwide propel the pharmaceutical & biotechnology companies worldwide"
Pharmaceutical & biotechnology companies are spearheading the end user segment for pharmaceutical intermediates market. The key drivers associated with its dominating market growth are rising prevalence of life threatening diseases and stringent regulatory norms pertaining to cGMP and cGLP guidelines for drug manufacturing imposed by healthcare agencies worldwide. Research laboratories have shown impressive growth in the last 2 decades on account of increasing demand for pharmaceutical intermediates in developing novel medicines for treating rare and autoimmune diseases. Contract manufacturing organization will be highlighting rampant growth during the forecast period on account of increasing demand for generic medicines due to patent expiration of blockbuster drugs in the near future and significant rise in drug manufacturing outsourcing activities to penetrate untapped market worldwide.
Get a sample copy for more information
"Presence of well developed healthcare infrastructure and rising public health awareness together drive the market growth in North America"
North America presently holds 35.8% market growth and is the largest regional segment for pharmaceutical intermediates market. The drivers responsible for its positive market growth are presence of well developed healthcare infrastructure and rising public health awareness. Europe is placed second I the regional segment representing 30.4% market share on account of significant rise in patient population seeking medical intervention for life threatening diseases and supportive regulatory environment provided by European Medical Agency (EMA) for pharmaceutical intermediates market. Asia Pacific is accountable for 20.2% market share owing to proactive government policies resulting in flourishing drug manufacturing activities and serves as a lucrative market opportunity for western giants to enter into strategic collaboration and agreement with local players owing to the flourishing generic drug market in Asia Pacific region.
Historical & Forecast Period
This research report presents the analysis of each segment from 2017 to 2027 considering 2018 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segments are calculated for the forecast period from 2019 to 2027.
Report Scope by Segments
The market segmentation comprises of by product, end user and geography.
| ATTRIBUTE |
DETAILS |
| Research Period |
2017-2027 |
| Base Year |
2018 |
| Forecast Period |
2019-2027 |
| Historical Year |
2017 |
| Unit |
USD Million |
| Segmentation |
By Product (2017–2027; US$ Mn)
• Bulk Drug Intermediates
• Chemical Intermediates
• Custom Intermediates
|
|
By End User (2017–2027; US$ Mn)
• Pharmaceutical and Biotechnology Companies
• Contract Manufacturing Organization
• Research Laboratories
|
|
Geography Segment (2017–2027; US$ Mn)
• North America (U.S., Canada)
• Europe (U.K., Germany, Rest of Europe)
• Asia Pacific (China, Japan, Rest of Asia Pacific)
• Latin America (Brazil, Mexico, Rest of Latin America)
• Middle East and Africa (GCC, Rest of MEA)
|
Companies producing pharmaceutical intermediates are BASF SE, Bristol Myers Squibb Company, Cambrex Corporation, Chiracon GmbH, Codexis, Inc., Dishman Group, Dextra Laboratories, Ltd., Lonza, Midas Pharma GmbH and Vertellus Holdings LLC.
Key questions answered in this report
- Which pharmaceutical companies are competing in the pharmaceutical intermediates market?
- What are the latest DRO’s pertaining to pharmaceutical intermediates market?
- Why is bulk intermediates the leading product segment?
- What will be the market performance of contract manufacturing organization?
- What will be the market size and CAGR of Asia Pacific, Latin America and Middle East and Africa during the forecast period?
